Free Trial

Revvity Inc. (NYSE:RVTY) to Issue $0.07 Quarterly Dividend

Revvity logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Dividend: Revvity declared a quarterly dividend of $0.07 per share (annualized $0.28) payable Aug. 7 to holders of record on July 17, implying a yield of ~0.3% and a payout ratio of about 5.1%, indicating the dividend is well covered by earnings.
  • Quarterly results & guidance: Revvity beat estimates with Q results of $1.70 EPS (vs. $1.55 expected) and $772.06M revenue (up 5.9% y/y), and set FY2026 guidance of $5.35–$5.45 EPS, near the street forecast of $5.39.
  • Stock snapshot: Shares traded down ~1.1% to $85.66, with a market cap of $9.58B, a P/E of ~41.3, and a 52‑week range of $81.22–$118.30.
  • Five stocks we like better than Revvity.

Revvity Inc. (NYSE:RVTY - Get Free Report) declared a quarterly dividend on Thursday, April 30th. Stockholders of record on Friday, July 17th will be given a dividend of 0.07 per share on Friday, August 7th. This represents a c) dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th.

Revvity has a payout ratio of 5.1% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Revvity to earn $5.99 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 4.7%.

Revvity Trading Down 1.1%

Shares of RVTY traded down $0.96 during mid-day trading on Friday, hitting $85.66. The company had a trading volume of 169,868 shares, compared to its average volume of 1,244,351. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36. The business's 50-day simple moving average is $90.39 and its 200-day simple moving average is $96.74. The stock has a market cap of $9.58 billion, a PE ratio of 41.28, a P/E/G ratio of 1.75 and a beta of 1.13.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The company had revenue of $772.06 million for the quarter, compared to the consensus estimate of $759.81 million. During the same quarter last year, the firm posted $1.42 earnings per share. Revvity's revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Sell-side analysts forecast that Revvity will post 5.39 earnings per share for the current year.

Institutional Investors Weigh In On Revvity

Several institutional investors and hedge funds have recently modified their holdings of RVTY. Ascentis Independent Advisors purchased a new stake in shares of Revvity during the 1st quarter valued at about $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the second quarter valued at approximately $32,000. Cromwell Holdings LLC raised its stake in shares of Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company's stock valued at $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc acquired a new position in shares of Revvity during the second quarter worth $34,000. Finally, Headlands Technologies LLC purchased a new position in shares of Revvity in the second quarter valued at $49,000. Hedge funds and other institutional investors own 86.65% of the company's stock.

About Revvity

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

Further Reading

Dividend History for Revvity (NYSE:RVTY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Revvity Right Now?

Before you consider Revvity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.

While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines